SEC Tracker
Get the app
FLNA · XBRL financial data

Filana Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (FLNA's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Research and development18,731*16,23315,19817,67620,530*13,6665,1163,9553,853*4,5443,3033,868
General and administrative4,058*3,70146,20412,9478,957*10,92040,2767,9059,699*6,6246,0907,406
Total operating expenses22,789*19,93461,40230,62329,487*24,58645,39211,86013,552*11,1689,39311,274
Operating income (loss)(22,789)*(19,934)(61,402)(30,623)(29,487)*(24,586)(45,392)(11,860)(13,552)*(11,168)(9,393)(11,274)
Other income (expense)291*160996290*(82)(46)(114)39*484328
Income tax expense (benefit)—0000*0000*000
Net income (loss)(20,919)*25,0436,155(27,943)(27,597)*(23,403)(44,224)(10,807)(12,539)*(10,331)(8,603)(10,726)
Earnings per share, basic USD per share(0.50)*0.580.13(0.58)—(0.48)(0.92)(0.22)(0.26)*(0.21)(0.18)(0.22)
Earnings per share, diluted USD per share—(0.43)0.13(0.58)(0.57)*(0.48)(0.92)(0.22)(0.26)*———
Weighted average shares, basic thousands of shares42,188*43,00146,20247,97648,099*48,26248,30848,30848,309*———
Weighted average shares, diluted thousands of shares42,188*44,10246,20247,97648,104*48,26248,30848,30848,309*———

Balance sheet

CSV

Fiscal quarters (FLNA's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents121,136124,169207,291148,978128,574117,328112,381106,08095,50286,57382,68146,990
Prepaid and other current assets8,4979,83014,83113,5717,9582,8232,4402,8302,2071,3911,0421,817
Total current assets129,633133,999222,122202,549136,532120,151114,821108,91097,70987,96483,72380,057
Property and equipment, net21,85421,60421,36421,13520,96420,78120,56320,82320,64620,40320,18020,001
Right-of-use asset0———————————
Total assets151,663155,718243,568223,753157,533140,932135,384129,733118,355108,367103,903100,058
Total current liabilities14,19577,12154,59457,03411,75013,23747,33248,04643,83440,11540,15841,946
Lease liability, non-current0———————————
Total liabilities14,195——57,11411,82913,31647,41148,16543,95240,22640,29442,082
Accumulated deficit(380,769)(355,726)(349,571)(377,514)(405,111)(428,514)(472,738)(483,545)(496,084)(506,415)(515,018)(525,744)
Total stockholders' equity137,46878,597188,974166,639145,704127,61687,97381,56874,40368,14163,60957,976
Total liabilities and equity151,663155,718243,568223,753157,533140,932135,384129,733118,355108,367103,903100,058
Common shares outstanding (cover page) thousands of shares43,22547,97647,97648,11048,30848,30848,30848,30848,30848,30848,30850,270

Cash flows

CSV

Fiscal quarters (FLNA's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(20,919)*25,0436,155(27,943)(27,597)*(23,403)(44,224)(10,807)(12,539)*(10,331)(8,603)(10,726)
Stock-based compensation2,129*2,3352,604*5,608*5,744*5,2254,581*4,402*5,374*4,0694,071*3,476*
Net cash from operating activities(22,316)*(19,127)(18,241)*(18,296)*year only(11,336)(4,947)*(6,221)*(9,748)*(8,878)(3,855)*(6,094)*
Purchases of property and equipment41*029*17*57*00*80*501*——31*
Net cash from investing activities(41)*0(29)*(17)*(57)*00*(80)*(501)*——(31)*
Proceeds from issuing common stockyear only———year only———————
Net cash from financing activities1,143*22,160101,392*0*918*900*0*(329)*(51)(16)*1,684*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Filana Therapeutics46,990not reported(6,094)*50.3M7.5 quarters 10-QSep 30, 2026
Anixa Biosciences1,398not reported(1,770)*34.8M6.8 quarters 10-QJul 31, 2026
GENELUX9,184not reported(6,444)*45.2M2.9 quarters 10-QJun 30, 2026
Entera Bio11,3090(3,464)*173.1M3.3 quarters 10-QJun 30, 2026
Immunic155,098not reported(30,998)*13.6M5.0 quarters 10-QJun 30, 2026
Coherus Oncology82,923not reported(62,090)*154.5M1.7 quarters 10-QJun 30, 2026
Elicio Therapeutics30,900not reported(10,364)*28.3M3.1 quarters 10-QSep 30, 2026
Larimar Therapeutics92,687not reported(44,030)*103.9M3.5 quarters 10-QJun 30, 2026
DiaMedica Therapeutics5,129not reported(8,114)*53.9M5.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.